For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT02339571
EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim vervus Nivolumab plus Ipilimuman in Patients with Unresectable Stage III or Stage IV Melanoma
Contact Name:
Steven Schmitt
Study Type:
Oncology - Melanoma & Skin
Study Status:
Open to Accrual
Principal investigator:
Mei Tang, MD
IRB number :
810609
Study Number:
EA6141
Phone:
Fax:
ES-2021-05: Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer
Contact Name:
Study Type:
Oncology - Selected Cancers
Study Status:
Open to Accrual
Principal investigator:
Paul Celano, MD
IRB number :
2144060
Study Number:
ES-2021-05 (G2316)
Phone:
Fax:
This study collects a blood specimen, archival tumor tissue specimen, and specific medical history information. Patients with newly diagnosed cancers, and those with a new cancer recurrence are potential candidates. Please contact your GBMC oncologist to see if you may qualify for this study.
eVOLVE-HNSCC: A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Contact Name:
Study Type:
Oncology - Head and Neck
Study Status:
Open to Accrual
Principal investigator:
Mei Tang, MD
IRB number :
2187703
Study Number:
eVOLVE-HNSCC (G2314)
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06129864
eVOLVE-Lung02: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Contact Name:
Study Type:
Oncology - Pulmonary
Study Status:
Open to Accrual
Principal investigator:
Mei Tang, MD
IRB number :
2218080
Study Number:
D798AC00001 (G2404)
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05984277
EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)
Contact Name:
Study Type:
Oncology - Breast
Study Status:
Open to Accrual
Principal investigator:
Robert Donegan, MD
IRB number :
2213466
Study Number:
NSABP-B64 | EXActDNA-003 (G2402)
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06401421